Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update.

ABSTRACT:

Background

Primary analysis of the phase I/II clinical trial combining pembrolizumab with all-trans retinoic acid (ATRA) for patients with metastatic melanoma showed a median progression-free survival (PFS) of 20.3 months and median overall survival (OS) not reached.

Objective

Report 5-year OS and PFS rates.

Design

In this single-center, single-arm trial (NCT03200847), 24 anti-PD-1 naïve patients with metastatic melanoma were enrolled between 10/2017 and 07/2020.

Methods

The Kaplan-Meier method was used to estimate OS and PFS.

Results

At data cutoff (May 14, 2024), all patients had completed treatment, and 58% (n = 14) remained alive with a median follow-up of 48 months. The updated 5-year OS rate is 54.7% (95% confidence interval (CI): 36.4-82.1)

SUBMITTER: Borgers JSW 

PROVIDER: S-EPMC12198584 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature